Finanzen von Senti Biosciences Holdings Inc (SNTI)SNTISenti Biosciences Holdings Inc

Evaluating the bottom line, Senti Biosciences Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -85229.41%, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SNTI converts its operational activities into shareholder value.

In the context of the broader market, SNTI competes directly with industry leaders such as VTGN and MTVA. With a market capitalization of $12.10M, it holds a leading position in the sector. When comparing efficiency, SNTI's gross margin of N/A stands against VTGN's N/A and MTVA's N/A. Such benchmarking helps identify whether Senti Biosciences Holdings Inc is trading at a premium or discount relative to its financial performance.

Senti Biosciences has not generated revenue consistently, with a total revenue of only $22,000 expected in Q4 2025. The company reported a net income loss of $42.21 million in Q1 2026 and has a negative gross margin in recent quarters, reflecting ongoing operational difficulties.